武汉博欧特生物科技有限公司
入驻年限：11 年
- 联系人：
王定涛
- 所在地区：
湖北 武汉市 洪山区
- 业务范围：
试剂、抗体、ELISA 试剂盒、技术服务、体外诊断
- 经营模式：
代理商
推荐产品
公司新闻/正文
【Biorbyt新产品】COVID19 Biomarker Panel: 肽生物标志物预测COVID-19的严重性
人阅读 发布时间：2021-05-10 15:51
【Biorbyt新产品】COVID19 Biomarker Panel: 肽生物标志物预测COVID-19的严重性
原创 biorbyt 英国biorbyt 1周前收录于话题
#biorbyt44
#研究领域产品30
#新冠产品11
Tailored Biomarker Tests for COVID-19
针对COVID-19的量身定制的生物标志物测试
COVID-19 is an infectious disease caused by SARS coronavirus 2 (SARS-CoV-2) and is the cause of the COVID-19 pandemic. Scientists across the world are working together to accelerate the research and development process to contain its spread.
COVID-19是由SARS冠状病毒2（SARS-CoV-2）引起的传染病，是COVID-19大流行的原因。世界各地的科学家正在共同努力，加快研发进程，以遏制其传播。
Predictive COVID-19 Disease Severity Test / COVID-19 疾病严重程度预测试验
● The test classifies and predicts COVID-19 disease severity, based on host response to COVID-19.
该测试根据COVID-19的反应对COVID-19疾病的严重程度进行分类和预测。
●The test predicts whether COVID-19 patients:
该测试可预测COVID-19患者是否：
ⅰ. are likely to develop severe disease (WHO 3 vs WHO 4-7);
可能发展为严重疾病（WHO 3 vs WHO 4-7）；
ⅱ. will need invasive ventilation;
将需要有创通气；
ⅲ. are likely to survive if they have severe disease.
在患严重疾病的情况下存活下来。
● The purpose of the test is to demonstrate treatment efficacy, elucidate the MoA of COVID-19 therapeutics in development and to provide a readout of what the disease would have looked like without treatment.
该测试的目的是证明治疗效果，阐明正在开发的COVID-19治疗剂的MoA，并提供未经治疗的疾病外观的读数。
● The test may also be used as a tool for severe disease risk stratification in an exploratory context.
该测试还可以在探索性背景下用作严重疾病风险分层的工具。
Highlights
● A standardized, ultra-high-throughput clinical platform for serum and plasma proteomics
一个用于血清和血浆蛋白质组学的标准化超高通量临床平台
● Platform enables high precision quantification of 180 human proteomes per day at low cost
平台能够每天以低成本对180种人类蛋白质组进行高精度定量
● 27 biomarkers are differentially expressed between WHO severity grades for COVID-19
可以分析COVID-19不同WHO严重程度等级的27种生物标志物差异表达
● Biomarkers include proteins not previously associated with COVID-19 infection
生物标志物包括以前与COVID-19感染无关的蛋白质分析
Overlaid chromatogram of the biomarker peptides included in the multiplexed targeted proteomic assay. The assay was developed to quantitate 50+ peptides in a 10 min LC run.
多重靶向蛋白质组学分析中包括的生物标志物肽的重叠色谱图。开发了该分析方法，可在10分钟的LC运行中对50+肽段进行定量。
| Early Access Program 抢先体验计划 |
|
| Kit Reagents (Reference Peptides)/ 试剂盒试剂（参考肽） |
· 52 Synthetic reference peptides (calibrators) (approx 1ug per peptide per batch) / 52种合成参考肽（校准品）（每批每肽约1ug） · 52 Isotopically labelled internal standard peptides (approx 100ng per peptide per sample) / 52种同位素标记的内标肽（每个样品每个肽约100ng） |
| Quantity / Format /数量/格式 |
104 peptides in 2-3ml labelled Eppendorf vials 2-3毫升标记的Eppendorf小瓶中的104种肽 |
| Shipping /运输 |
Ambient temp. / 环境温度 |
| Storage /储存 |
Dried down & stored at -20 Celsius / 干燥&-20摄氏度下储存 |
| Shelf life /保质期 |
12 months /12个月 |
| Number of samples per kit / 每个盒子的样本数 |
80 |
| QCs and Calibrators / QC和校准品 |
16 |
| Protocols included (SOPs) /实验方案 |
A detailed, step-by-step protocol with SOPs for sample preparation, mass spectrometry system set up and the results we have generated previously /提供使用SOP，进行详细的分步操作的方案，用于样品制备，质谱系统设置以及我们先前生成的结果 |
Get your COVID-19 Biomarker Panel today
产品名称：COVID19 Biomarker Panel
产品货号: orb751448
产品链接：https://www.biorbyt.com/covid19-biomarker-panel-orb751448.html
or contact us for more information
References
1. Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A., Kreidl, M., Ludwig, D., Kilian, C., Agostini, F., Zelezniak, A., Thibeault, C., Pfeiffer, M., Hippenstiel, S., Hocke, A., von Kalle, C., Campbell, A., Hayward, C., Porteous, D. J., Marioni, R. E., Langenberg, C., Lilley, K. S., Kuebler, W. M., Mülleder, M., Drosten, C., Suttorp, N., Witzenrath, M., Kurth, F., Sander, L. E. and Ralser, M. 2020. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. Cell Systems, 11(1), 11-24.e4. Available from: doi: 10.1016/j.cels.2020.05.012
2. Demichev, V., Tober-Lau, P., Nazarenko, T., Thibeault, C., Whitwell, H., Lemke, O., Röhl, A., Freiwald, A., Szyrwiel, L., Ludwig, D., Correia-Melo, C., Helbig, E. T., Stubbemann, P., Grüning, N., Blyuss, O., Vernardis, S., White, M., Messner, C. B., Joannidis, M., Sonnweber, T., Klein, S. J., Pizzini, A., Wohlfarter, Y., Sahanic, S., Hilbe, R., Schaefer, B., Wagner, S., Mittermaier, M., Machleidt, F., Garcia, C., Ruwwe-Glösenkamp, C., Lingscheid, T., de Jarcy, L. B., Stegemann, M. S., Pfeiffer, M., Jürgens, L., Denker, S., Zickler, D., Enghard, P., Zelezniak, A., Campbell, A., Hayward, C., Porteous, D. J., Marioni, R. E., Uhrig, A., Müller-Redetzky, H., Zoller, H., Löffler-Ragg, J., Keller, M. A., Tancevski, I., Timms, J. F., Zaikin, A., Hippenstiel, S., Ramharter, M., Witzenrath, M., Suttorp, N., Lilley, K., Mülleder, M., Sander, L. E., Ralser, M. and Kurth,. 2020. A Time-Resolved Proteomic And Diagnostic Map Characterizes COVID-19 Disease Progression And Predicts Outcome. Cold Spring Harbor Laboratory. Available from: doi:10.1101/2020.11.09.20228015.
biorbyt拥有各种研究领域的抗体，蛋白和试剂盒，欢迎访问biorbyt全球官方网站（www.biorbyt.com）和中国网站（www.biorbyt.com.cn），或者拨打biorbyt中国办事处热线电话：400-966-3101；027-87663101。 或微信（电话）15307197287在线沟通。
询价列表
暂时没有已询价产品
